Aperio Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $35.7M | Sell |
145,780
-47,734
| -25% | -$12.3M | 0.11% | 187 |
|
|
2020
Q3 | $54.9M | Sell |
193,514
-16,716
| -8% | -$4.66M | 0.19% | 96 |
|
|
2020
Q2 | $56.2M | Sell |
210,230
-20,855
| -9% | -$6.27M | 0.21% | 91 |
|
|
2020
Q1 | $73.1M | Buy |
231,085
+20,614
| +10% | +$6.26M | 0.32% | 57 |
|
|
2019
Q4 | $62.5M | Sell |
210,471
-7,336
| -3% | -$2.04M | 0.22% | 85 |
|
|
2019
Q3 | $50.7M | Buy |
217,807
+84,560
| +63% | +$19.7M | 0.2% | 97 |
|
|
2019
Q2 | $31.2M | Sell |
133,247
-34,222
| -20% | -$7.9M | 0.13% | 176 |
|
|
2019
Q1 | $39.6M | Buy |
167,469
+6,990
| +4% | +$2.2M | 0.17% | 125 |
|
|
2018
Q4 | $48.3M | Buy |
160,479
+141
| +0.1% | +$45K | 0.24% | 81 |
|
|
2018
Q3 | $56.6M | Buy |
160,338
+8,256
| +5% | +$2.84M | 0.25% | 81 |
|
|
2018
Q2 | $44.1M | Buy |
152,082
+30,124
| +25% | +$8.47M | 0.21% | 101 |
|
|
2018
Q1 | $33.4M | Sell |
121,958
-4,590
| -4% | -$1.42M | 0.17% | 140 |
|
|
2017
Q4 | $40.3M | Buy |
126,548
+18,780
| +17% | +$6.02M | 0.2% | 105 |
|
|
2017
Q3 | $33.7M | Buy |
107,768
+12,007
| +13% | +$3.56M | 0.19% | 115 |
|
|
2017
Q2 | $26M | Sell |
95,761
-151
| -0.2% | -$39.9K | 0.16% | 146 |
|
|
2017
Q1 | $26.2M | Buy |
95,912
+2,498
| +3% | +$706K | 0.18% | 128 |
|
|
2016
Q4 | $26.5M | Sell |
93,414
-1,403
| -1% | -$416K | 0.2% | 106 |
|
|
2016
Q3 | $29.7M | Buy |
94,817
+5,454
| +6% | +$1.62M | 0.21% | 105 |
|
|
2016
Q2 | $21.6M | Buy |
89,363
+2,152
| +2% | +$567K | 0.17% | 142 |
|
|
2016
Q1 | $22.7M | Sell |
87,211
-1,896
| -2% | -$501K | 0.19% | 125 |
|
|
2015
Q4 | $27.3M | Buy |
89,107
+6,423
| +8% | +$1.85M | 0.25% | 88 |
|
|
2015
Q3 | $24.1M | Buy |
82,684
+418
| +0.5% | +$138K | 0.25% | 92 |
|
|
2015
Q2 | $33.2M | Buy |
82,266
+4,556
| +6% | +$1.83M | 0.34% | 58 |
|
|
2015
Q1 | $32.8M | Buy |
77,710
+7,338
| +10% | +$2.89M | 0.37% | 50 |
|
|
2014
Q4 | $23.9M | Buy |
70,372
+3,310
| +5% | +$1.07M | 0.29% | 70 |
|
|
2014
Q3 | $22.2M | Buy |
67,062
+6,248
| +10% | +$2.06M | 0.3% | 68 |
|
|
2014
Q2 | $19.2M | Buy |
60,814
+935
| +2% | +$281K | 0.28% | 73 |
|
|
2014
Q1 | $18.3M | Buy |
+59,879
| New | +$19M | 0.26% | 69 |
|
|
2013
Q4 | – | Sell |
-49,697
| Closed | -$12.9M | – | 80 |
|
|
2013
Q3 | $12M | Buy |
49,697
+6,403
| +15% | +$1.43M | 0.23% | 90 |
|
|
2013
Q2 | $9.32M | Buy |
+43,294
| New | +$9.25M | 0.22% | 93 |
|
Other funds holding BIIB
Aperio Group's BIIB Position: Q4 2020 in Review
Aperio Group reduced its Biogen (BIIB) stake by 25% in Q4 2020, selling an estimated $12.3M and leaving 145,780 shares worth $35.7M. The position accounts for 0.11% of the portfolio, ranked #187.
Aperio Group first reported a position in BIIB in Q2 2013 and has held it in 30 quarters since. The position peaked at $73.1M in Q1 2020. 1,061 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.
- Aperio Group held 145,780 shares of Biogen worth $35.7M as of Q4 2020.
- Aperio Group sold 47,734 Biogen shares in Q4 2020, an estimated $12.3M.
- Biogen made up 0.11% of Aperio Group's portfolio in Q4 2020, its #187 holding.
- Aperio Group first reported a position in Biogen in Q2 2013 and has held it in 30 quarters since.
- Aperio Group's Biogen position peaked at $73.1M in Q1 2020.
- 1,061 funds tracked by Wall St. Rank held Biogen as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.